These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19046770)

  • 1. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
    J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
    Betting DJ; Mu XY; Kafi K; McDonnel D; Rosas F; Gold DP; Timmerman JM
    Vaccine; 2009 Jan; 27(2):250-9. PubMed ID: 19000731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
    Neelapu SS; Baskar S; Kwak LW
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
    Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
    Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M; Ochi A
    J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
    Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
    Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
    Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
    J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.